A dispute over a common asthma drug leaves patients caught in the middle ...Middle East

The Hill - News
A dispute over a common asthma drug leaves patients caught in the middle
The most common asthma inhaler for children was discontinued at the start of this year, forcing parents and pediatricians to scramble to switch to an alternative.   But more than a month later, the situation has not improved, and families remain caught in the middle of a fight between a drug company and pharmacy benefit managers (PBMs) with no end in sight.  Manufacturer GlaxoSmithKline (GSK) stopped making Flovent on Jan. 1 and is instead offering an “authorized generic” version distributed through a different company. It’s the same drug, just without the branding.   GSK introduced the authorized generic of Flovent HFA in May 2022. It has a lower list price than the brand name,

Hence then, the article about a dispute over a common asthma drug leaves patients caught in the middle was published today ( ) and is available on The Hill ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( A dispute over a common asthma drug leaves patients caught in the middle )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News